Dianthus Therapeutics, Inc. /DE/ Increase (Decrease) in Accounts Receivable
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Increase (Decrease) in Accounts Receivable of $54.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$1.12M.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $1.18M, a 17.80% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$4.95M.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $4.96M.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in accounts receivable for fiscal 2025 was $52.00K.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in accounts receivable for fiscal 2024 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $54.00K 10-Q · filed 2026-08-04 | -$4.89M derived: sum of 3 quarters · filed 2026-08-04 | $67.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $1.18M 10-Q · filed 2026-05-05 | -$3.77M derived: sum of 2 quarters · filed 2026-05-05 | $1.19M derived: sum of 3 quarters · filed 2026-05-05 | $230.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$4.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $13.00K derived: sum of 2 quarters · filed 2026-03-09 | -$948.00K derived: sum of 3 quarters · filed 2026-08-04 | $52.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $4.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.00M derived: sum of 2 quarters · filed 2026-08-04 | $5.00M 10-Q · filed 2025-11-05 | $5.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$961.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $39.00K 10-Q · filed 2026-08-04 | $39.00K derived: sum of 3 quarters · filed 2026-08-04 | $39.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-05 | $1.00M derived: sum of 2 quarters · filed 2026-05-05 | $1.00M derived: sum of 3 quarters · filed 2026-05-05 | $1.00M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |